CoreMap today announced it closed a $20 million Series B financing to accelerate the development of its cardiac arrhythmia diagnostic technology and launch pilot studies.
The Burlington, Vermont–based company said it also closed on a $3 million Series A Milestone financing that was part of its $10.5 million Series A in September 2020. In addition, CoreMap won a National Science Foundation research grant that same month after participating as one of the startups in MassMEDIC’s IGNITE virtual accelerator when the program relaunched in 2019.
CoreMap said pre-clinical and clinical studies have successfully demonstrated the CoreMap System, which consists of the company’s high-resolution Invenio catheter and VidereX workstation.
“We have a catheter that will go inside the heart to record the electrical activity with high spatial resolution and create unambiguous electrograms. And that’s not possible today with today’s technology,” co-founder and CEO Sarah Kalil said yesterday in an interview with Medical Design & Outsourcing ahead of the announcement.